Document is current
Any future updates will be listed below
-
Authors
Lu, Xinyan
Chen, Dongshi https://orcid.org/0000-0002-8973-5606
Wang, Min
Song, Xiangping
Ermine, Kaylee
Hao, Suisui
Jha, Anupma
Huang, Yixian
Kang, Ying
Qiu, Haibo https://orcid.org/0009-0000-3283-8359
Lenz, Heinz-Josef https://orcid.org/0000-0003-2178-9568
Li, Song https://orcid.org/0000-0003-1658-949X
Jin, Zhendong https://orcid.org/0000-0003-1672-513X
Yu, Jian https://orcid.org/0000-0002-4021-1000
Zhang, Lin https://orcid.org/0000-0003-0018-3903
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA217141, R01CA236271, R01CA247231, R01CA248112, R01CA203028, R01CA215481, R01CA260900)
Start-up funds from the Keck School of Medicine of USC
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM133332)
- License Information
-
More Information
Article History
Received: 9 June 2024
Revised: 18 April 2025
Accepted: 30 April 2025
First Online: 6 May 2025
Competing interests
: ZJ is the founder and a shareholder of InnoBioPharma, LLC, a spin-off from the University of Iowa, focusing on the development of novel payloads for ADCs from natural products like OSW-1. InnoBioPharma sponsored the project, “Development of novel anticancer agents based on natural products” at the University of Iowa.
: This study was reviewed and approved by the ethics committees of the University of Pittsburgh and University of Southern California. All methods including laboratory animal experiments were performed in accordance with the relevant guidelines and regulations of the University of Pittsburgh and University of Southern California.
